Covered recipient · General Payments record
LUIS MARTINEZ
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$3,036.89
- Reported across 96 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $853.49 | 3 |
| Food and Beverage | $473.02 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Moderna TX, Inc. | $1,159.49 | 8 |
| Novo Nordisk AS | $63.52 | 3 |
| Teva Pharmaceuticals USA, Inc. | $62.80 | 3 |
| Amgen Inc. | $34.61 | 2 |
| PFIZER INC. | $6.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.25 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117320302 | CMS |
| Amgen Inc. | $19.36 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117320304 | CMS |
| ModernaTX, Inc. | $240.00 | 09/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1152560444 | CMS |
| ModernaTX, Inc. | $347.96 | 09/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1152560448 | CMS |
| ModernaTX, Inc. | $265.53 | 09/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1152560454 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152560468 | CMS |
| ModernaTX, Inc. | $81.00 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152560470 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152560472 | CMS |
| ModernaTX, Inc. | $45.00 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152560474 | CMS |
| ModernaTX, Inc. | $120.00 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152560476 | CMS |
| Novo Nordisk Inc | $22.12 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097386249 | CMS |
| Novo Nordisk Inc | $17.74 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096888652 | CMS |
| Novo Nordisk Inc | $23.66 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096814197 | CMS |
| PFIZER INC. | $6.09 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132017114 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.30 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151757654 | CMS |
| Teva Pharmaceuticals USA, Inc. | $23.25 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151757656 | CMS |
| Teva Pharmaceuticals USA, Inc. | $20.25 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151757686 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.